Related Experiment Videos
[Placebo-controlled comparative study of clenbuterol and terbutaline in asthmatic children]
Insights
Clenbuterol demonstrated significant improvements in pediatric lung function, including FEV1, PMF, and VC, compared to terbutaline and placebo. This bronchodilator showed a favorable safety profile in the studied pediatric population.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacology
Background:
- Asthma and other pediatric respiratory conditions require effective bronchodilator therapy.
- Comparing the efficacy and safety of different bronchodilators is crucial for optimizing treatment.
Purpose of the Study:
- To compare the clinical and spirometric efficacy and safety of clenbuterol against terbutaline and placebo in pediatric patients.
- To assess the impact of clenbuterol on specific lung function parameters in children.
Main Methods:
- A single-blind, randomized, prospective, and observational study involving 30 pediatric patients.
- Patients were divided into three groups: clenbuterol, terbutaline, and placebo.
- Lung function was assessed using spirometry, measuring FEV1, PMF, and VC.
Main Results:
- Clenbuterol treatment resulted in statistically significant improvements in FEV1 (Forced Expiratory Volume in 1 second), PMF (Peak Maximal Flow), and VC (Vital Capacity).
- Terbutaline and placebo groups did not show comparable significant improvements in these spirometric parameters.
- Reported side effects for clenbuterol were minor and deemed unimportant.
Conclusions:
- Clenbuterol is an effective bronchodilator for pediatric patients, showing significant improvements in lung function parameters.
- The safety profile of clenbuterol in this pediatric cohort was favorable.
- Clenbuterol presents a viable therapeutic option for pediatric respiratory conditions requiring bronchodilation.
Abstract:
In order to evaluate clinically and spirometrically the efficacy and safety of clenbuterol in comparison with terbutaline and placebo, 30 pediatric patients, in three groups of ten subjects each one, were studied. The study was designed single blind with control group (placebo), randomized, prospective and observational. Total average age was 8.2 years, weight 29 kg and size 130 cm. Nineteen subjects were male and 11 female. Group I received clenbuterol (0.0012 mg/kg/day) solution bid during one week; group II received terbutaline (0.075 mg/kg/day) solution tid and group III, placebo. There were differences statistically significant in the group treated with clenbuterol in FEV1, PMF and VC. Side effects were without importance.